EUVIMEDEUVIMED entdecken
Crossref

Pharmaco-virological Outcomes and Genotypic Resistance Profiles Among Children and Adolescents Receiving a Dolutegravir-Based Regimen in Togo

Yao Rodion Konu, Elom Takassi, Gilles Peytavin, Nina Dapam, Florence Damond, Wone Adama Oumarou, Meryem Zaidi, Anna-Maria Franco-Yusti, Claver A Dagnra, Quentin Le Hingrat, Romain Coppée, Diane Descamps und 3 weitere

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciae278 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Yao Rodion Konu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Faculté des Sciences de la Santé, Département de Santé Publique, Université de Lomé, Lomé, Togo. Hauptthemen laut MEDLINE: HIV Infections, Drug Resistance, Viral, HIV-1, Heterocyclic Compounds, 3-Ring. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: World Health Organization, WHO, Agence Nationale de Recherche sur le SIDA et les Hépatites Virales.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Few data are available on the real-world efficacy of receiving tenofovir-lamivudine-dolutegravir (-DTG) as human immunodeficiencyvirus (HIV) treatment, particularly among young people in West Africa. Here, we evaluated pharmaco-virological outcomes and resistance profiles among Togolese children and adolescents.

Methods

A cross-sectional study was conducted in Lomé, Togo, enrolling antiretroviral-treated people with HIV aged from 18 months to 24 years. Plasma HIV-1 viral load and antiretroviral concentrations were measured. Next-generation sequencing of protease, reverse transcriptase (RT), and integrase was performed on all samples with viral loads >200 copies/mL. Drug resistance mutations (DRMs) were identified and interpreted using the ANRS-MIE algorithm.

Results

264 participants were enrolled (median age, 17 years); 226 received a DTG-based regimen for a median of 20.5 months. Among them, there was virological suppression at the 200-copies/mL threshold in 80.0% of the participants. Plasma DTG concentrations were adequate (ie, >640 ng/mL), suboptimal, and below the limit of quantification in 74.1%, 6.7%, and 19.2% of participants receiving DTG, respectively. Overall, viruses resistant to any of nucleoside RT inhibitors, non-NRTIs, and protease inhibitors were found in 52%, 66%, and 1.6% of participants, respectively. A major integrase inhibitor DRM was observed in 9.4% (n = 3/32; R263K, E138A-G140A-Q148R, and N155H) of participants with a viral load >200 copies/mL.

Conclusions

These first findings in a large series of adolescents in a low-income country showed a good virological response of 80% and the presence of an integrase DRM in 9.4% of virological failures, supporting the need to monitor DTG drug resistance to reduce the risk of resistance acquisition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsDrug Resistance, ViralHIV-1Heterocyclic Compounds, 3-RingAnti-HIV AgentsHumansAdolescentChildPyridonesFemaleMaleCross-Sectional StudiesTogoViral LoadChild, PreschoolInfantPiperazinesOxazinesGenotypeYoung AdultTreatment OutcomeTenofovirLamivudineHIV Integrase InhibitorsDolutegravir

Stichwörter der Autor:innen

HIVTogochildren/adolescentsdolutegravirresistance

Substanzen

PyridonesHeterocyclic Compounds, 3-RingPiperazinesOxazinesAnti-HIV AgentsTenofovirLamivudineHIV Integrase InhibitorsDolutegravir

Autor:innen und Institutionen

  • Faculté des Sciences de la Santé, Département de Santé Publique, Université de Lomé, Lomé, Togo.
  • Centre Africain de Recherche en Epidémiologie et en Santé Publique (CARESP), Lomé, Togo.
  • Service de Pédiatrie, CHU Sylvanus Olympio, Université de Lomé, Lomé, Togo.
  • Service de Pharmacologie, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale (INSERM), Infections, Antimicrobials, Modeling, Evolution (IAME), UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard…
  • Espoir Vie Togo, Lomé, Togo.
  • Service de Virologie, Université Paris Cité, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France.

Förderung

  • World Health Organization
  • WHO
  • Agence Nationale de Recherche sur le SIDA et les Hépatites Virales

Zitieren

APA

Konu, Y. R., Takassi, E., Peytavin, G., Dapam, N., Damond, F., Oumarou, W. A., Zaidi, M., Franco-Yusti, A. M., Dagnra, C. A., Le Hingrat, Q., Coppée, R., Descamps, D., Diallo, F. B. T., Ekouevi, D. K., & Charpentier, C. (2025). Pharmaco-virological Outcomes and Genotypic Resistance Profiles Among Children and Adolescents Receiving a Dolutegravir-Based Regimen in Togo. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae278

Vancouver

Konu YR, Takassi E, Peytavin G, Dapam N, Damond F, Oumarou WA, et al. Pharmaco-virological Outcomes and Genotypic Resistance Profiles Among Children and Adolescents Receiving a Dolutegravir-Based Regimen in Togo. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae278

BibTeX
@article{Konu2025,
  author = {Konu, Yao Rodion and Takassi, Elom and Peytavin, Gilles and Dapam, Nina and Damond, Florence and Oumarou, Wone Adama and Zaidi, Meryem and Franco-Yusti, Anna-Maria and Dagnra, Claver A and Le Hingrat, Quentin and Coppée, Romain and Descamps, Diane and Diallo, Fatoumata Binta Tidiane and Ekouevi, Didier K and Charpentier, Charlotte},
  title = {Pharmaco-virological Outcomes and Genotypic Resistance Profiles Among Children and Adolescents Receiving a Dolutegravir-Based Regimen in Togo},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciae278}
}
Kostenlos starten →